PERCEPTION ENABLED TECHNOLOGY
ZARTAUXFILL+ GF is an advanced CE-marked hyaluronic acid (HA) dermal filler utilizing S.C.E.D.I.S. (Stable Cross-linking Enhanced Dermal Integration System) technology, designed for safe and effective medical applications. This monophasic, monodensified HA gel enhances skin hydration, restores volume, and improves elasticity, addressing concerns such as facial wrinkles, scars, and facial lipoatrophy. Based on clinical evaluations, ZARTAUXFILL+ GF integrates seamlessly with skin tissues, delivering natural-looking results with a favorable safety profile.
Overview of S.C.E.D.I.S. Technology
S.C.E.D.I.S. technology is a proprietary cross-linking method that distinguishes ZARTAUXFILL+ GF from traditional HA dermal fillers. Unlike conventional techniques that may alter the HA molecule’s structure, S.C.E.D.I.S. employs divinyl sulfone (DVS) as a cross-linking agent to create a stable, monophasic, monodensified gel. This process preserves the natural characteristics of HA, a naturally occurring polysaccharide in the human body known for its hydrating and volumizing properties. By maintaining the integrity of the HA molecule, S.C.E.D.I.S. minimizes the risk of adverse reactions, ensuring the filler integrates seamlessly with the body’s tissues and degrades naturally without leaving harmful residues.
MONOPHASIC & MONODENSIFIED
ZARTAUXFILL+ GF’s monophasic, monodensified composition ensures a uniform, cohesive gel with consistent viscoelastic properties. Unlike biphasic fillers, which combine cross-linked and non-cross-linked HA, this structure promotes even distribution and tissue integration, minimizing migration risks. Clinical evaluations demonstrate that the gel’s elasticity supports effective volume restoration, making it suitable for applications such as nasolabial fold correction, lip augmentation, scar revision, and treatment of facial lipoatrophy, as specified in the device’s intended purpose.
RHEOLOGICAL PROPERTIES
ZARTAUXFILL+ GF exhibits high viscosity and elasticity (G’ values approximately 200–300 Pa), enabling effective volume restoration and resistance to deformation under facial muscle movement. The gel’s cohesivity ensures smooth injection and even distribution, minimizing the risk of lumps or the Tyndall effect in superficial applications. These properties support its use in both superficial and deep dermal injections for wrinkles, scars, and facial lipoatrophy, as specified in the device’s instructions for use.
CLINICAL ADVANTAGES
The S.C.E.D.I.S. technology enhances ZARTAUXFILL+GF’s performance in several key areas
BIOCOMPATIBILITY
The preservation of HA’s natural properties reduces the likelihood of adverse reactions, such as inflammation or nodule formation, when used as directed.
​​
DURABILITY
DVS cross-linking enhances resistance to enzymatic degradation, with effects lasting 12–18 months in clinical evaluations, depending on the treatment area and patient factors.
VERSATILITY
The monophasic, monodensified gel is adaptable for various medical applications, including nasolabial fold correction, lip augmentation, and scar revision, offering clinicians flexibility in addressing patient-specific needs.
SAFETY PROFILE
The filler is fully resorbable and reversible with hyaluronidase, providing a mechanism to manage rare complications like vascular occlusion. Potential side effects, such as temporary swelling, bruising, or redness, are consistent with HA filler use.
FUTURE IMPLICATIONS
ZARTAUXFILL+ GF’s S.C.E.D.I.S. technology raises the bar for HA dermal fillers by combining safety, efficacy, and longevity. Its innovative approach aligns with emerging trends in aesthetic medicine, such as the development of fillers that promote tissue regeneration alongside physical filling. As the demand for minimally invasive procedures grows, ZARTAUXFILL+ GF is poised to lead the market, offering clinicians and patients a reliable, high-performance solution for facial rejuvenation.